The phase III FLAURA study revealed that NSCLC patients treated with osimertinib had a significantly prolonged progression‐free survival (PFS) and overall survival (OS) than those treated with first‐generation EGFR‐TKI as first‐line treatment (PFS: 18.9 months vs. 10.2 months; OS: 38.6 months vs. 31.8 months).3, 4. This evidence concerns the gene EGFR and non-small cell lung carcinoma.